Table 2.
Research progress of new drugs to target PD-1.
| Medicine | Research institute | Application | Clinical phase |
|---|---|---|---|
| Nivolum (Opdivo) | Ono Pharmaceutical and Bristol-Myers-Squibb | Non-small cell lung cancer, malignant melanoma, renal cell carcinoma, head and neck squamous cell carcinoma, urothelium carcinoma, colorectal cancer, liver cancer, classical hodgkin lymphomas | 2014-06 (Marketing) |
| Pembrolizumab (Keytruda) | Merck | Non-small cell lung cancer, malignant melanoma, renal cell carcinoma, head and neck squamous cell carcinoma, urothelium carcinoma, colorectal cancer, liver cancer, classical hodgkin lymphomas | 2014-09 (Marketing) |
| Cemiplimab (Libtayo) | Sanofi and Regeneron | Metastatic squamous cell carcinoma of the skin | 2018-09 (Marketing) |
| Toripalimab | Shanghai Junshi Biosciences (China), Suzhou Zhonghe Biomedical Technology (China) | Hepatocellular carcinoma, melanoma | 2018-12 (Marketing) |
| Sintilimab | Innovent (China), Eli Lilly and Company | Hodgkin lymphomas | 2018-12 (Marketing) |
| Camrelizumab | Jiangsu Hengrui Medicine (China) | Esophageal squamous cell carcinoma, advanced solid-tumor, hepatocellular carcinoma, hodgkin lymphomas | 2019-05 (Marketing) |
| Tislelizumab | Beigene (China), Celgene, Boehringer-Ingelheim | Urothelium carcinoma, hodgkin lymphomas | 2019-12 (Marketing) |
| CX-188 | CytomX Therapeutics | Solid tumors | Phase I clinical trial |
| Sym-021 | Symphogen | Solid tumors, lymphomas | Phase I clinical trial |
| STW204 | Stainwei Biotech (China) | Solid tumors | Phase I clinical trial |
| Millamolecule | Bristol-Myers-Squibb | Immune diseases | Phase I clinical trial |
| XmAb20717 | Xencor | Solid tumors | Phase I clinical trial |
| CC-90006 | AnaptysBio, Celgene | Autoimmune diseases, psoriasis | Phase I clinical trial |
| YBL-006 | Y Biologics | Advanced solid-tumor | Phase I clinical trial |
| ONO-4685 | Merus, Ono Pharmaceutical | Autoimmune diseases | Phase I clinical trial |
| MGD-019 (MacroGenics) | MacroGenics | Solid tumors | Phase I clinical trial |
| SL-279252 | Shattuck Labs | Gastric adenocarcinoma, non-small cell lung cancer, diffuse large b cell lymphoma, renal cell carcinoma, urothelium carcinoma, solid tumors, head and neck squamous cell carcinoma, hodgkin lymphomas, adeno-carcinoma of esophagogastric junction, melanoma | Phase I clinical trial |
| RG-6084 | Roche | Hepatitis B | Phase I clinical trial |
| AMP-224 | Amplimmune, MedImmune, National Cancer Institute, GlaxoSmithKline | Solid tumors, colorectal cancer | Phase I clinical trial |
| PD-1 knockout engineered T cells | Cell Biotech | Renal cell carcinoma, prostatic cancer bladder cancer | Phase I clinical trial |
| IMU-201 | Imugene | Non-small cell lung cancer | Phase I clinical trial |
| MEDI-5752 | MedImmune | Solid tumors | Phase I clinical trial |
| JTX-4014 | Jounce Therapeutics | Cancer | Phase I clinical trial |
| RO-7247669 | Roche | Solid tumors | Phase I clinical trial |
| Budigalimab | Abbvie | Non-small cell lung cancer, solid tumors, colorectal cancer, ovarian cancer | Phase I clinical trial |
| LY-3434172 | Eli Lilly and Company | Solid tumors | Phase I clinical trial |
| INCB-086550 | Incyte | Solid tumors | Phase I clinical trial |
| MEDI-0680 | MedImmune | B cell lymphoma | Phase II clinical trial |
| EDP-1503 | The University of Chicago, Evelo Biosciences, Merck Sharp & Dohme | Melanoma | Phase II clinical trial |
| BCD-217 | Biocad | Melanoma | Phase II clinical trial |
| Balstilimab | Agenus, Ludwig Institute for Cancer Research | Solid tumors, cervical cancer | Phase II clinical trial |
| BI-754091 | Boehringer-Ingel heim | Solid tumors | Phase II clinical trial |
| TY-101 | Tayu Biotech | Solid tumors, lymphomas | Phase II clinical trial |
| GS-4224 | Gilead Sciences | Solid tumors | Phase II clinical trial |
| CA-170 | Aurigene, Curis | Cancer | Phase II clinical trial |
| MGD-013 | MacroGenics, ZaiLab (China) | Gastric cancer, esophageal cancer | Phase III clinical trial |
| Sasanlimab | Pfizer | Bladder cancer | Phase III clinical trial |
| Retifanlimab | MacroGenics, Incyte, ZaiLab (China) | Gastric cancer, esophageal cancer | Phase III clinical trial |
| Spartalizumab | Novartis | Melanoma | Phase III clinical trial |
| Cetrelimab | Johnson & Johnson | Multiple myeloma | Phase III clinical trial |
| Nivolumab/Relatlimab | Bristol-Myers-Squibb | Melanoma | Phase III clinical trial |
| Dostarlimab | AnaptysBio, Tesaro, GlaxoSmithKline | Fallopian tube cancer, endometrial cancer, peritoneal cancer, ovarian cancer | BLA |
| Zimberelimab | Gloria Pharmaceuticals (China), WuXi AppTec (China), Arcus Biosciences | Triple negative breast cancer, gastric cancer, solid tumors, liver cancer, hodgkin lymphomas | BLA |